Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites
Status:
COMPLETED
Trial end date:
2025-05-14
Target enrollment:
Participant gender:
Summary
This trial adopts random, double-blind, positive control, parallel group design to evaluate the effectiveness and safety of recombinant human serum albumin versus human serum albumin in hepatic cirrhosis patients with ascites.
Phase:
PHASE2
Details
Lead Sponsor:
Protgen Ltd
Treatments:
recombinant human serum albumin-heme Serum Albumin, Human